# A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer

> **NCT00116779** · PHASE2 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 127 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Degarelix

## Key facts

- **NCT ID:** NCT00116779
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2005-08
- **Final completion:** 2005-08
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2011-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00116779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00116779, "A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00116779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*